Boston Scientific wins Canadian approval for two new cardiac devices

When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features. According to the company, the Cognis cardiac resynchronization therapy defibrillator and the Teligen implantable cardioverter defibrillator are designed to eliminate those compromises. Both the devices are claimed to be the world’s smallest and thinnest high-energy devices at 32.5cc and 31.5cc, respectively, while being less than 10mm thick.

They offer innovative features based on significant engineering advances, including extended battery longevity, self-correcting software and improved programming technology, the company said.

Fred Colen, president of cardiac rhythm management at Boston Scientific, said: “We are very pleased with the positive customer response to Cognis and Teligen since the US launch in August 2008 and look forward to a successful launch in Canada.”